Regeneron Pharmaceuticals (REGN) Statistics

Regeneron Pharmaceuticals Inc (REGN) is a leading biotechnology company that focuses on the discovery, development, and commercialization of innovative medicines for serious diseases. The company's stock statistics demonstrate its strong performance in the market. Over the past year, REGN stock has shown impressive growth, outpacing the overall sector. Its valuation metrics also indicate its solid market position and potential for future growth. With a high price-to-earnings ratio and strong revenue growth, REGN is considered a valuable investment opportunity. Moreover, its fundamentals, such as its strong pipeline of drugs and robust financial position, further support its positive outlook.

REGN's stock performance has consistently outperformed its sector, reflecting the company's strong market position and investor confidence. The stock's revenue per share has also been impressive, demonstrating the company's ability to generate substantial revenue from its products. Moreover, REGN's Enterprise to EBITDA ratio, a measure of its profitability, is favorable, indicating efficient operations and solid financial performance. Furthermore, the company's profit margin is noteworthy, reflecting its ability to generate profit from its sales. While REGN does have a significant amount of total debt, its strong gross profit suggests that the company has the ability to manage and repay its debt obligations.